Sabato 27 ottobre 2012 - Pacini Editore
Sabato 27 ottobre 2012 - Pacini Editore
Sabato 27 ottobre 2012 - Pacini Editore
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
392<br />
was smooth. Both ovaries were involved enterely by white solid,<br />
firm, yellow, grey tissue. Histologically, booth ovarian tumor<br />
were composed of uniform spindle cells arranged in sheets and<br />
intersecting fascicles. The stroma showed loose areas as well as<br />
more fibrous areas containing intercellular collagen. In some areas,<br />
thick hyaline fibrous plaques could be observed. The nuclei<br />
were bland and slim with pointed ends and indistinct nucleoli.<br />
The neoplastic cells were positive for vimentin. S100, desmin,<br />
h-caldesmon, C10, HMB45, muscle-specific actin, estrogen, progesterone<br />
receptors, CD31, and c-KIT were negative. The mitotic<br />
count varied from 4 to 6 per 10 HPF (Fig. 2). The Ki-67 proliferation<br />
index was low (< 1%). No significant atypia or necrosis<br />
could be observed. Eighteen months after the surgery, no sign of<br />
new recurrence was noted.<br />
Discussion. The histologic criteria of ovarian FTs are controversial.<br />
In 1981, Prat and Scully 1 proposed histologic criteria for the<br />
distinction of cellular fibromas (CFs) from fibrosarcomas (Fs).<br />
These authors found that mitotic activity was the most important<br />
factor in diagnosing the sarcomas, and that nuclear grading<br />
with cellular pleomorphism was not so much reliable. CFs were<br />
characterized by densely cellular proliferations of fibroblasts<br />
with mild to moderate nuclear atypia, a mitotic count of 3 or<br />
fewer mitotic figures (MFs) per 10 HPFs, and a low malignant<br />
potential 1 . In contrast, Fs usually exhibited moderate to severe<br />
nuclear atypia, mitotic counts of 4 or more MFs/10 HPFs, and a<br />
clinically malignant course in most cases 1 . After the first study<br />
published by Prat and Scully 1 a number of ovarian Fs with a benign<br />
clinical course have been reported in the literature in which<br />
the diagnosis was based on a mitotic count of 4 or more mitotic<br />
figures/10HPFs 2 . The Atlas of Tumor Pathology, published by<br />
Armed Forces Institute of Pathology and the World Health Organization<br />
Classification of Tumours are the textbooks of choice<br />
consultation for pathologists in the diagnosis of tumour. Scully<br />
et al. 3 believe that pure Fs are among the most common forms<br />
of ovarian sarcoma. Microscopic examination shows a densely<br />
cellular neoplasm with moderate to severe nuclear atypia and an<br />
average mitotic count of 4 or more per 10 HPFs. Abnormal mitotic<br />
figures and areas of necrosis and hemorrhage are common 3 .<br />
In the Chapter “Sex cord-stromal tumours” of the World Health<br />
Organization Classification of the Breast and Female Genital<br />
Organs, Tavassoli et al. 4 considered ovary F as a rare fibroblastic<br />
tumour that typically has 4 or more mitotic figures per 10 high<br />
power fields as well as significant nuclear atypia. Irving et al. 5<br />
believe that cellular FT with bland nuclear feaures and mitotic<br />
count of ≥ 4 MFs/10 HPFs should be considered a mitotically active<br />
cellular fibroma of the ovary (MACF) rather than an ovarian<br />
F. The latter term should be reserved for fibroblastic tumors that<br />
exhibit a combination of moderate to severe atypia and a usually<br />
high mitotic rate.<br />
Conclusions. Our cases may be classified as Fs according to Prat<br />
and Scully 1 histological criteria of and as MACFs of the ovary<br />
according to Irving et al. 5 criteria. Because of the controversial<br />
diagnostic criteria, we prefer the terminology ovarian fibromatous<br />
tumours of uncertain biological potential when an average<br />
mitotic count of 4 or more per 10HPFs are found and nuclear<br />
atypia and necrosis are absent. This term reflect the controversial<br />
prognosis of these tumors. The management of choice of these<br />
lesions consist of exclusive strict radiological follow-up, in order<br />
to monitoring recurrences or metastases.<br />
references<br />
1 Prat J, Scully RE. Cellular fibromas and fibrosarcomas of the ovary:<br />
a comparative clinicopathologic analysis of seventeen cases. Cancer<br />
1981;47:2663-70.<br />
2 Gultekin M, Dursun P, Ozyuncu O, et al. Primary ovarian fibrosarcoma:<br />
a case report and review of the literature. Int J Gynecol Cancer<br />
2005;15:1142-7.<br />
3 Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped<br />
Gonads, Fallopian Tube, and Broad Ligament. Published by the<br />
CONGRESSO aNNualE di aNatOmia patOlOGiCa SiapEC – iap • fiRENzE, 25-<strong>27</strong> OttOBRE <strong>2012</strong><br />
Armed Forces Institute of Pathology, Washington, D.C. 3rd series.<br />
Fascicle 23, p. 197.<br />
4 Tavassoli FA, Mooney E, Gersell DJ, et al. “Sex cord-stromal tumours”<br />
of the World Health Organization Classification of the Breast<br />
and Female Genital Organs. Edited by Fattaneh A. Tavassoli & Peter<br />
Devilee. Lyon: IARCPress 2003, p. 151.<br />
5 Irving JA, Alkushi A, Young RH, et al. Cellular fibromas of the ovary:<br />
a study of 75 cases including 40 mitotically active tumors emphasizing<br />
their distinction from fibrosarcoma. Am J Surg Pathol 2006;30:929-38.<br />
InTErESSE GEnErALE<br />
P16 and CK20, immunocytochemical double<br />
staining in urinary cytology: method optimization<br />
R. Rapezzi, B. Selmi, G. Ferro, P. Crucitti, S. Negri, A. Bondi<br />
U.O. Anatomia, Istologia Patologica e citodiagnostica, Ospedale Maggiore,<br />
Azienda USL di Bologna<br />
Background. Every year more than 7000 patients attend to Anatomic<br />
Pathology Unit (UO) of Maggiore Hospital in Bologna to<br />
perform an urine cytological test.<br />
Since 2009 access to this service has been progressively increased<br />
by introducing a new procedure for sample collection by addiction<br />
of alcohol based fixative capable of retaining cellular elements<br />
well preserved and stable for 7 days at least.<br />
The urinary cytology test has an important role in the follow up of<br />
patients treated for urothelial cancer, with a high specificity (95-<br />
100%) but low sensitivity (38-60%) due to difficulty to correctly<br />
distinguish between florid benign lesions from well-differentiated<br />
carcinomas. Therefore immunocytochemical investigations may<br />
be useful in the follow-up of cystectomized patient or evaluation<br />
of hyperplastic lesions.<br />
Loss of heterozygosity at chromosome 9, where houses the<br />
regulation of p16 synthesis, is an aberration found in urothelial<br />
cell carcinoma of all stage and grade as well as in dysplastic<br />
urothelium, possibly representing an early event in urinary bladder<br />
carcinogenesis.. The expression of P16 protein represents an<br />
indirect estimate of the most common genetic alteration found in<br />
bladder cancer and an indication of its ability to replicate. P16 INK4a<br />
is not found in non-neoplastic urothelium, while is expressed in<br />
50% of urothelial carcinoma, increasing to 80% in high-grade<br />
carcinomas.<br />
CK20 is a high molecular weight cytokeratin little or not expressed<br />
in normal urothelium, while it is clearly present in transitional<br />
carcinomas.<br />
Materials and methods. In our laboratory, samples are obtained<br />
by simultaneous and complete filtration of 3 samples by a filtration<br />
system with a vacuum pump of about 25 mmHg average<br />
pressure and a polycarbonate membranes of ø 5 microns pore. For<br />
each patient a single glass is set up, stained with Papanicolaou,<br />
and produces a single diagnosis. The same analyzed material is<br />
then used for immunocytochemical investigations.<br />
P16 analysis was performed by a CINtec antibody into the Ventana<br />
BenchMark XT. Initially the detection system used was<br />
Phosphatase Red Detection Kit, where positivity is shown by<br />
nucleus / cytoplasm red staining.<br />
CK20 analysis was performed by an antibody anti-CK20 also into<br />
the Ventana BenchMark XT. Initially the detection system used<br />
was UltraView Universal DAB Detection Kit and positivity was<br />
detectable as a brown cytoplasmic staining.<br />
However CK20 positivity, revealed by DAB, completely masked<br />
P16 positivity revealed by Red.<br />
Having a single slide, we developed a double immunocytochemical<br />
staining: P16 has been detected in brown with diaminobenzidine<br />
(DAB) increasing incubation times and with<br />
an amplification system and CK20 was detected in Red, after<br />
appropriate reduction of time and incubation temperature of<br />
primary antibody.